A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery
Bethanechol 100 mg twice daily is well tolerated in patients with PDAC in this small phase 0/window of opportunity study (NCT03572283). Bethanechol treatment was associated with decreased Granzyme B positive cells and decreased circulating IL-18 consistent with an anti-inflammatory role for parasympathetic muscarinic signaling in PDAC.
Authors
- Helen Remotti (ORCID: https://orcid.org/0000-0003-1555-9299)
- Susan E. Bates (ORCID: https://orcid.org/0000-0001-6708-0330)
- Paul E. Oberstein (ORCID: https://orcid.org/0000-0001-5918-6004)
- Gulam A. Manji (ORCID: https://orcid.org/0000-0001-9817-2414)
- Kazuki N. Sugahara (ORCID: https://orcid.org/0000-0002-4946-192X)
- John A. Chabot
- Beth Schrope (ORCID: https://orcid.org/0000-0003-0313-8120)
- Michael D. Kluger (ORCID: https://orcid.org/0000-0003-4311-078X)
- Timothy C. Wang (ORCID: https://orcid.org/0000-0001-5730-3019)
- Ruth A. White (ORCID: https://orcid.org/0000-0002-4274-4468)
- Qiongyu Shi
- Valeria Mezzano-Robinson
- Nadine Kuriakose
Institutions
- Columbia University Irving Medical Center (US)
- NYU Langone Health (US)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- New York University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-31
- DOI
- https://doi.org/10.1093/oncolo/oyaf162
- Citations
- 2
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- U.S. Department of Defense
- Conquer Cancer Foundation
- Pancreatic Cancer Action Network
- American Society of Clinical Oncology
- National Institutes of Health
- National Cancer Institute
- National Institute of Dental and Craniofacial Research